与myc结合亲和力高的已上市药物

MYC有所谓不可成药性，还没有专门的靶向药上市。
# p" w6 {4 z. g$ M
' z' a. C' t2 {4 ]' p6 _目前针对myc实际可行的治疗策略是根据患者除myc突变扩增外的其他突变，抑制其他靶点，如mtor、hsp90等，实现合成致死或蛋白降解。自救群里部分myc扩增的乳腺癌患者用了mtor抑制剂，确有疗效。

* Z1 G1 g' b+ |. Y) B5 v) X针对治疗myc还有一种办法是通过计算机虚拟筛选等办法，在已上市药物里找与myc结合亲和力高的药物。

& K9 w! {* }* n6 ~+ s《In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia》这篇论文，通过Virtual Screening、Molecular Docking Analyses and Microscale Thermophoresis的办法，从FDA已经批准上市的1578种药物里，筛选出一些与MYC结合亲和力高的药物；其中一些药物与MYC的结合亲和力超过常用的c-MYC 抑制剂试剂 10058-F4 和 10074-G5(LBEs of −4.92 kcal/mol and −6.24 kcal/mol)。
! {8 k% f! k3 P" Z0 B* ?
下面是结合亲和力比较强的一些药物：
5 Q2 {, C5 n* o
( D/ }" @5 q& r, e( ?5 x


- b+ `/ Y  a8 [4 _1 g其他一些研究的结论与这篇论文的结论是相印证的，试举几例如下：

% x$ p5 S4 R6 ^' r7 d
1、《Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors》
3 Z( {* l% H: A2 C
& H$ g, ]$ s8 o: b“MYC was identified as the most statistically repressed gene by DHE”

$ b5 G+ E0 S  X  m/ b& f
6 x! F7 m) ~8 T- L  L5 O
2、《Drug repurposing and prediction of multiple interaction types via graph embedding》
/ _2 l/ x# @. a; K& p
( d$ s% {, v* h“Two FDA approved drugs, Dihydroergotamine (CHEMBL1732) and Indinavir Sulfate (CHEMBL1735), which are predicted by the DT2Vec+, might be able to target MYC and decrease its expression. ”

+ q9 }5 Z( x" t' |4 c$ n, [  J; M
+ {$ u) T# w6 n* `
3、《Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells》
) h0 n! `: M' D" ^6 n1 G7 }3 J
“PNT induced apoptosis (increased sub G1 cells, and cleaved caspase3 and PARP), and suppressed protein expression of MCL1, cyclin D2 and c-myc, which were reversed by a proteasome inhibitor, MG132, suggesting enhanced proteasomal degradation by PNT. ”
% q" m* {& h5 E& _8 f4 J7 T
0 R. ^+ u& k  V
4、《 Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer》

" n( ~3 H: n, Y+ I+ d Additionally, treatment with eribulin resulted in a decrease in c-myc expression and a trend
, p& d, I+ {# \, `. k5 C# y2 Y) Xtoward an increase in cdki p15。

7 e& V' o8 X5 g$ J. n
. k4 U6 i% c# e$ H9 E1 `5、《Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2/β-catenin signaling》
' A) A, e  ~; w5 s3 n
& Z6 z" q6 h; e; d$ T“We also observed a decrease in c-Myc expression in the tumors of atovaquone-treated mice”